RenovoRx Inc (RNXT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $50.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
RenovoRx Inc (RNXT) Stock Forecast
Analysts expect RenovoRx (RNXT) to earn -$0.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.86M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 196.1%.
- Fiscal year ending Dec 31, 2026
- -$0.27
- EPS consensus, revenue $3.86M
- Fiscal year ending Dec 31, 2027
- -$0.12
- EPS consensus, revenue $11.43M
- Next report
- Mar 29, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.27 | -$0.27 to -$0.27 | 1 | $3.86M | $3.70M to $4.04M | 4 |
| Dec 31, 2027 | -$0.12 | -$0.20 to -$0.04 | 2 | $11.43M | $10.00M to $14.01M | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.06 for the quarter ending Dec 31, 2026 to -$0.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.07 to -$0.03 | 6 | $1.37M | $1.14M to $1.58M | 6 |
| Mar 31, 2027 | -$0.05 | -$0.06 to -$0.03 | 2 | $1.54M | $1.40M to $1.71M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.27 | -$0.27 | -$0.27 | -$0.27 | -$0.31 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.12 | -$0.12 | -$0.12 | -$0.12 | -$0.15 | N/A |
| Quarter ending Mar 31, 2027 | -$0.05 | -$0.05 | -$0.05 | -$0.05 | -$0.07 | N/A |
Frequently Asked Questions About RNXT
What is the RNXT stock forecast?
Consensus analyst estimates put RenovoRx's EPS at -$0.27 for the fiscal year ending Dec 31, 2026, on revenue of $3.86M. The consensus rating from 4 analysts is Buy.
How do analysts rate RNXT stock?
Of 4 analysts covering RenovoRx, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RNXT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.27, with estimates from -$0.27 to -$0.27 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.12, with estimates from -$0.20 to -$0.04 from 2 analysts.
What revenue do analysts expect from RenovoRx next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.86M, with estimates from $3.70M to $4.04M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.43M, with estimates from $10.00M to $14.01M.
How many analysts cover RNXT?
4 analysts rate RenovoRx stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
RNXT pages: Overview, Earnings, Forecast, Financials, Competitors